Real Cases, Key Takeaways: Applying Atopic Dermatitis Insights in Clinical Practice
June 9th 2025Panelist discusses how patient cases demonstrate the importance of considering nonsteroidal agents in patients of color (due to hypopigmentation risks) and elderly patients (due to skin thinning), concluding that effective atopic dermatitis management requires proper moisturizing, appropriate corticosteroid cycling, and proactive twice-weekly maintenance with newer nonsteroidal topicals to prevent long-term complications.
Stronger Together: Collaborating With Dermatologists for Better Outcomes
June 9th 2025Panelist discusses how referral to dermatology should occur when patients fail to reach treatment goals despite proper skincare, appropriate topical steroid and nonsteroid use, and proactive treatment, emphasizing the importance of maintaining open dialogue about systemic therapy options rather than dismissing them as “last resort” treatments.
Tailoring Treatment: Personalizing Topical Therapy for Patients With Atopic Dermatitis
June 9th 2025Panelist discusses how topical treatment selection should be based on affected body areas, patient preferences for vehicle type, and disease extent, noting that patients prefer topical over systemic therapies and emphasizing the importance of using specialty pharmacies with manufacturer contracts to ensure affordable access through proper prior authorization processes.
Beyond Steroids: Clinical Trial Results on the Next Generation Agents for Atopic Dermatitis
June 9th 2025nonsteroidal topicals including roflumilast (next-generation PDE4 inhibitor), ruxolitinib (JAK1/2 inhibitor), and tapinarof (aryl hydrocarbon receptor agonist) offer significant improvements in efficacy and tolerability compared with older agents like crisaborole, with clinical trial data showing 30% to 50% of patients achieving complete or near-complete clearance.
The Topical Toolbox: A Review of Atopic Dermatitis Treatment Options
June 9th 2025Panelist discusses how the current treatment guidelines include 4 classes of topical therapies, with newer nonsteroidal options like JAK inhibitors and PDE4 inhibitors providing effective alternatives to long-term corticosteroid use.
Recognizing and Diagnosing Atopic Dermatitis With Confidence
June 9th 2025Panelist discusses how the atopic dermatitis treatment landscape has evolved with new nonsteroidal topical therapies that can match the effectiveness of corticosteroids without their associated adverse effects and long-term risks.
Closing Thoughts on Treating Anaphylaxis with Epinephrine Nasal Spray
May 21st 2025A panelist discusses how education about anaphylaxis recognition, early epinephrine administration, and addressing barriers like device portability remains crucial, with intranasal epinephrine potentially solving many existing challenges in anaphylaxis management.
Real-World Case Examples: The Impact of Epinephrine Nasal Spray
May 21st 2025A panelist discusses how real-world cases demonstrate both the effectiveness of epinephrine when properly administered and the importance of ensuring patients actually carry their medication, through the stories of a college student with cashew allergy and a child undergoing a peanut challenge.
Clinical Perspectives on Real-World Utility and Impact of Epinephrine Nasal Spray
May 21st 2025A panelist discusses how Neffy offers significant advantages over traditional autoinjectors, including longer shelf life (24-30 months), better temperature tolerance, and needle-free administration that addresses several unmet needs in anaphylaxis management.
Oral Food Challenge (OFC) Study with Epinephrine Nasal Spray
May 21st 2025A panelist discusses how a study of Neffy (epinephrine nasal spray) in Japan demonstrated effectiveness in treating 15 pediatric patients who experienced grade 2 allergic reactions during oral food challenges, with these moderate reactions including symptoms like abdominal pain, vomiting, wheezing, and mild cardiovascular effects according to the updated grading system from professional allergy societies.
Addressing Barriers to Epinephrine Use: From Reluctance to Readiness
May 21st 2025A panelist discusses how patient uncertainty about when to administer epinephrine and reluctance to use autoinjectors are major barriers to timely treatment, with over 40% not filling their prescriptions and 55% to 60% not consistently carrying their devices.
Why Epinephrine Is the Gold Standard in Treating Anaphylaxis
May 21st 2025A panelist discusses how epinephrine is definitively the first-line treatment for anaphylaxis regardless of severity, emphasizing that delayed administration is associated with poor outcomes, including abnormal vital signs and increased risk of hospitalization.